Gilead Says Remdesivir Hit Primary Target in Covid-19 Study
https://www.bloomberg.com/news/articles/2020-04-29/gilead-remdesivir-trial-for-covid-19-has-met-primary-endpoint
Gilead Sciences Inc. said data from a U.S. study of its drug remdesivir showed the medication had met the primary endpoint in a trial of its effectiveness in treating Covid-19.The company said in a statement that it is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ study of remdesivir for treating the disease caused by the novel coronavirus.Gilead shares were halted, but the news appeared to lift the entire U.S. stock market, with futures linked to major U.S. indexes jumping after the company’s statement was issued.
- Forums
- ASX - By Stock
- Media Updates
Gilead Says Remdesivir Hit Primary Target in Covid-19...
-
-
- There are more pages in this discussion • 9,929 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
(20min delay)
|
|||||
Last
$6.39 |
Change
0.040(0.63%) |
Mkt cap ! $4.568B |
Open | High | Low | Value | Volume |
$6.30 | $6.40 | $6.27 | $2.966M | 468.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 12531 | $6.38 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.39 | 19155 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 8890 | 6.370 |
21 | 18125 | 6.360 |
11 | 13896 | 6.350 |
12 | 21075 | 6.340 |
15 | 30048 | 6.330 |
Price($) | Vol. | No. |
---|---|---|
6.380 | 9826 | 16 |
6.390 | 12015 | 12 |
6.400 | 21535 | 12 |
6.410 | 29739 | 10 |
6.420 | 7961 | 8 |
Last trade - 12.53pm 09/10/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online